Beta Drugs Limited

Q4FY24 Concall highlights:

• Ebidta declined due to high RM cost (platin which is a gold n platinum derivative)
• Platin cost comprises 14-15% sales
• Platin can’t be manufactured in house.
• Yearly sales breakup:
  – Branded: 89 Cr (margin 33-36%)
  – CDMO: 140 Cr (margin 15-17%)
  – Exports: 46 Cr (margin 28-32%)
  – API : 21 Cr (margin 22-23%)
  – Derma: 6.83 Cr
• halfyearly sales breakup:
  – Branded: 41.5 Cr
  – CDMO: 68 Cr
  – Export: 30 Cr
  – API: 11 Cr
  – Derma: 3.3 Cr
• Ebidta will try to bring to 26% in FY25
• Cosmotology:
  – division posted net loss
  – guidance FY25 min sales 14-15 Cr
  – gross margin is 65%
  – plant setup initiate by Fy25-26 ( 30 – 35 Cr)
  – recently launched 5 products (haircare, sunscreen, moisturizer)
  – Will focus on hair product segment
  – Future target 35% of business
  – Dr prescribed medicine after Dr approves.
• Cleared audit n received registration cert from Urasia
• Cytotoxic syrup facility started
• Own brand, injectable: Oral = 43 : 57
• FY25 guidance 25-30% sales.
• 70% Api in house manufactured.
• 2-3 months will migrate to main board, process already initiated.
• export business target 35% business in future.